TABLE 1.
Emerging drugs for heart failure therapeutics targeting AT1R or APJ.
| Name of drug | Drug class | Model studied/clinical trials |
| TRV120027 | β-arrestin-biased AT1R agonist | ADHF (Phase 2B BLAST-AHF, no benefit over placebo) |
| TRV120023 | β-arrestin-biased AT1R agonist | DCM (mice, improved contractility) |
| ACI (mice/rats, improved contractility, reduced cell death) | ||
| TRV120067 | β-arrestin-biased AT1R agonist | DCM (mice, improved contractility and structure) |
| Sildenafil | PDE5 inhibitor | HFpEF (Phase 3 RELAX, no benefit over placebo) |
| HFrEF (Phase 3 SIL-HF, recruiting) | ||
| BI 749327 | TRPC6 inhibitor | CHF (mice, improved LV function and reduced fibrosis) |
| ML233 | small molecule APJ agonist | No reports on HF |
| AMG 986 | small molecule APJ agonist | CHF (Phase 1, terminated) |
| MM07 | G-protein-biased peptide APJ agonist | No reports on HF |
| CLR325 | peptide APJ agonist | CHF (Phase 2, completed) |
ADHF, acute decompensated heart failure; DCM, dilated cardiomyopathy; ACI, acute cardiac injury; CHF, chronic heart failure.